<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135707</url>
  </required_header>
  <id_info>
    <org_study_id>HD36801-CAPPS</org_study_id>
    <secondary_id>U10HD021410</secondary_id>
    <secondary_id>U10HD027869</secondary_id>
    <secondary_id>U10HD027917</secondary_id>
    <secondary_id>U10HD027860</secondary_id>
    <secondary_id>U10HD027915</secondary_id>
    <secondary_id>U10HD034116</secondary_id>
    <secondary_id>U10HD034208</secondary_id>
    <secondary_id>U10HD034136</secondary_id>
    <secondary_id>U10HD040500</secondary_id>
    <secondary_id>U10HD040485</secondary_id>
    <secondary_id>U10HD040544</secondary_id>
    <secondary_id>U10HD040545</secondary_id>
    <secondary_id>U10HD040560</secondary_id>
    <secondary_id>U10HD040512</secondary_id>
    <secondary_id>U01HD036801</secondary_id>
    <secondary_id>U10HD053097</secondary_id>
    <secondary_id>U10HD053118</secondary_id>
    <nct_id>NCT00135707</nct_id>
  </id_info>
  <brief_title>Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)</brief_title>
  <acronym>CAPPS</acronym>
  <official_title>A Randomized Clinical Trial of Antioxidants to Prevent Preeclampsia and An Observational Cohort Study to Predict Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Washington University Biostatistics Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Washington University Biostatistics Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preeclampsia is one of the most common complications of pregnancy and is characterized by
      high blood pressure and protein in the urine. This can cause problems in the second half of
      pregnancy for both the mother and fetus. This study of preeclampsia consists of two parts: 1)
      a randomized, placebo controlled, multicenter clinical trial of 10,000 low-risk nulliparous
      women between 9 and 16 weeks gestation and 2) an observational, cohort study of 4,000
      patients between 9 and 12 weeks gestation who are also enrolled in the trial.

      Subjects in both parts will receive either 1000 mg of vitamin C and 400 IU of vitamin E or
      matching placebo daily. The purpose of the randomized, clinical trial is to find out if high
      doses of vitamin C and E will reduce the risk of preeclampsia and other problems associated
      with the disease. The study will also evaluate the safety of antioxidant therapy for mother
      and infant. Patients will be seen monthly to receive their supply of study drug, to have
      weight and blood pressure recorded, to have urine protein measured, and to assess any side
      effects. At two visits, blood and urine will be collected.

      The observational, cohort study will prospectively measure potential biochemical and
      biophysical markers that might predict preeclampsia. These patients will have additional
      procedures including uterine artery Doppler and blood drawn for a complete blood count (CBC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Clinical Trial of Antioxidants to Prevent Preeclampsia:

      Preeclampsia is the leading cause of maternal morbidity, as well as perinatal morbidity and
      mortality. Once the diagnosis has been established, therapy other than delivery has not been
      successful except to prolong pregnancy minimally (at some risk to mother and infant).
      Prevention efforts to reduce or eliminate preeclampsia are directed at the pathophysiology of
      the disorder prior to clinically evident preeclampsia and before irreversible changes have
      occurred.

      This double-masked, placebo-controlled trial of 10,000 subjects is designed to evaluate the
      effects of antioxidant therapy in preventing serious complications associated with
      pregnancy-related hypertension in low risk, nulliparous women who begin treatment at 9-16
      weeks gestation. The hypothesis being tested is that antioxidant therapy initiated prior to
      16 weeks gestation will reduce the frequency of serious maternal and infant complications
      associated with pregnancy-related hypertension.

      After randomization, subjects will receive either 1000 mg of vitamin C and 400 IU of vitamin
      E or matching placebo daily. They will be seen for monthly pill counts and to assess side
      effects, weight, blood pressure, and urine for protein. Blood and urine are collected at 24
      and 32 weeks' gestation.

      An Observational Cohort Study to Predict Preeclampsia:

      A prospective, cohort study has been designed to complement the randomized, controlled, trial
      (RCT) and will test various biochemical and biophysical markers for ability to predict
      preeclampsia in 4,000 of the women who are enrolled in the RCT and are between 9 and 12 weeks
      gestation. These subjects will have additional procedures including a CBC and uterine artery
      Doppler.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate</measure>
    <time_frame>20 weeks through discharge following delivery</time_frame>
    <description>Severe hypertension (blood pressure [BP]&gt;= 160/110) or mild hypertension (BP&gt;= 140/90) &gt;= 20 weeks gestation in conjunction with one of the following: elevated liver enzymes, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, an indicated preterm birth before 32 weeks of gestation owing to hypertension-related disorders, a fetus that was small for gestational age (below 3rd percentile) adjusted for sex and race or ethnic group, fetal death after 20 weeks of gestation, or neonatal death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe Hypertension</measure>
    <time_frame>20 weeks through discharge following delivery</time_frame>
    <description>Included here are women who had severe hypertension only and those who had severe hypertension with elevated liver enzyme levels, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, medically indicated preterm birth, fetal-growth restriction, or fetal death after 20 weeks of gestation, or neonatal death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe or Mild Pregnancy-associated Hypertension With Elevated Liver Enzyme Levels</measure>
    <time_frame>20 weeks through discharge following delivery</time_frame>
    <description>Elevated liver enzyme levels are specified as an aspartate aminotransferase level of &gt;= 100 U per liter. Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe or Mild Pregnancy-associated Hypertension With Thrombocytopenia</measure>
    <time_frame>20 weeks through discharge following delivery</time_frame>
    <description>Thrombocytopenia defined as a platelet count of &lt;100,000 per cubic millimeter. Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe or Mild Pregnancy-associated Hypertension With an Elevated Serum Creatinine Level</measure>
    <time_frame>20 weeks through discharge following delivery</time_frame>
    <description>Elevated serum creatinine defined as ≥1.5 mg per deciliter or 132.6 μmol per liter. Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe or Mild Pregnancy-associated Hypertension With an Eclamptic Seizure</measure>
    <time_frame>20 weeks through discharge following delivery</time_frame>
    <description>Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe or Mild Pregnancy-associated Hypertension With an Indicated Preterm Birth Before 32 Weeks of Gestation Owing to Hypertension-related Disorders</measure>
    <time_frame>20 weeks through discharge following delivery</time_frame>
    <description>Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe or Mild Pregnancy-associated Hypertension With a Fetus That Was Small for Gestational Age (Below the 3rd Percentile) Adjusted for Sex and Race or Ethnic Group</measure>
    <time_frame>20 weeks through discharge following delivery</time_frame>
    <description>Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe or Mild Pregnancy-associated Hypertension With a Fetal Death After 20 Weeks of Gestation or Neonatal Death</measure>
    <time_frame>20 weeks through discharge or prior to discharge following delivery admission</time_frame>
    <description>Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preeclampsia (Mild, Severe, HELLP Syndrome, Eclampsia)</measure>
    <time_frame>20 weeks through discharge following delivery</time_frame>
    <description>HELLP denotes hemolytic anemia, elevated liver enzymes, and low platelet count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Associated Hypertension</measure>
    <time_frame>20 weeks through discharge following delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medically Indicated Delivery Because of Hypertension</measure>
    <time_frame>20 weeks through discharge following delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase ≥100 U/Liter</measure>
    <time_frame>20 weeks through discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine ≥1.5 mg/dl (133 μmol/Liter)</measure>
    <time_frame>20 weeks through discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antepartum Bleeding</measure>
    <time_frame>During pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premature Rupture of Membranes</measure>
    <time_frame>During pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental Abruption</measure>
    <time_frame>During pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cesarean Delivery</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Death</measure>
    <time_frame>Delivery through hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum Pulmonary Edema</measure>
    <time_frame>After delivery through discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit ≤24% With Transfusion</measure>
    <time_frame>Delivery admission to discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Hospital Stay</measure>
    <time_frame>Delivery through discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational Age at Delivery</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm Birth</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal or Neonatal Death</measure>
    <time_frame>During pregnancy or thorugh discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth Weight</measure>
    <time_frame>At birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small for Gestational Age</measure>
    <time_frame>At birth</time_frame>
    <description>A baby whose birth weight is less than the 3rd percentile is considered to be small for gestational age (adjusted for sex and race or ethnic group)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth Weight &lt;2500 Grams</measure>
    <time_frame>At birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to NICU</measure>
    <time_frame>Delivery through discharge</time_frame>
    <description>NICU denotes neonatal intensive care unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Distress Syndrome</measure>
    <time_frame>Delivery through discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraventricular Hemorrhage, Grade III or IV</measure>
    <time_frame>Delivery through discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sepsis</measure>
    <time_frame>Delivery through discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotizing Enterocolitis</measure>
    <time_frame>Delivery through discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinopathy of Prematurity</measure>
    <time_frame>Within 1 month of birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar Score &lt;=3 at 5 Minutes</measure>
    <time_frame>At birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Hospital Stay</measure>
    <time_frame>Birth through discharge from hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10154</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Dietary Supplement/Vitamins</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000mg of Vitamin C and 400IU of Vitamin E per capsule, twice daily between randomization (at 9 to 16 weeks) up to delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Vitamin C and Vitamin E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules consisting of Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell, twice daily between randomization (at 9 to 16 weks) up to delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dietary Supplement/Vitamins</intervention_name>
    <description>Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.</description>
    <arm_group_label>Dietary Supplement/Vitamins</arm_group_label>
    <other_name>Ascorbic Acid and d-alpha-Tocopheryl Acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Vitamin C and Vitamin E</intervention_name>
    <description>Placebo two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.</description>
    <arm_group_label>Placebo for Vitamin C and Vitamin E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        RCT Inclusion Criteria:

          -  Gestational age 9 -16 weeks

          -  Singleton pregnancy

          -  Nulliparous

        Observational Inclusion Criteria:

          -  Women randomized to the RCT

          -  Gestational age 9 - 12 wks

        Exclusion Criteria RCT and Observational:

          -  BP &gt;= 135/85

          -  Proteinuria

          -  History or current use of anti-hypertensive medication or diuretics

          -  Use of vitamins C &gt; 150 mg and/or E &gt; 75 IU per day

          -  Pregestational diabetes

          -  Current pregnancy is a result of in vitro fertilization

          -  Regular use of platelet active drugs or non-steroidal anti-inflammatory drugs (NSAIDS)

          -  Known fetal abnormalities

          -  Documented uterine bleeding within a week of screening

          -  Uterine malformations

          -  History of medical complications

          -  Illicit drug or alcohol abuse during current pregnancy

          -  Intent to deliver elsewhere

          -  Participating in another interventional study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Menachem Miodovnik, MD</last_name>
    <role>Study Director</role>
    <affiliation>NICHD Project Scientist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rebecca Clifton, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University Biostatistics Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James M Roberts, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh - Magee Womens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Magee Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bsc.gwu.edu/mfmu/</url>
    <description>The public website of the NICHD Maternal-Fetal Medicine Units (MFMU) Network</description>
  </link>
  <reference>
    <citation>Hauth JC, Clifton RG, Roberts JM, Myatt L, Spong CY, Leveno KJ, Varner MW, Wapner RJ, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Tolosa JE, Saade G, Sorokin Y, Anderson GD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal insulin resistance and preeclampsia. Am J Obstet Gynecol. 2011 Apr;204(4):327.e1-6. doi: 10.1016/j.ajog.2011.02.024.</citation>
    <PMID>21458622</PMID>
  </reference>
  <reference>
    <citation>Carreno CA, Clifton RG, Hauth JC, Myatt L, Roberts JM, Spong CY, Varner MW, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Sciscione A, Tolosa JE, Saade GR, Sorokin Y; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Excessive early gestational weight gain and risk of gestational diabetes mellitus in nulliparous women. Obstet Gynecol. 2012 Jun;119(6):1227-33. doi: 10.1097/AOG.0b013e318256cf1a. Erratum in: Obstet Gynecol. 2012 Sep;120(3):710. Saade, George R [added].</citation>
    <PMID>22617588</PMID>
  </reference>
  <reference>
    <citation>Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, Varner MW, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Iams JD, Sciscione A, Harper M, Tolosa JE, Saade G, Sorokin Y, Anderson GD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol. 2012 Jun;119(6):1234-42. doi: 10.1097/AOG.0b013e3182571669.</citation>
    <PMID>22617589</PMID>
  </reference>
  <reference>
    <citation>Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, Varner MW, Wapner RJ, Thorp JM Jr, Mercer BM, Grobman WA, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Harper M, Tolosa JE, Saade G, Sorokin Y, Anderson GD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units Network (MFMU). The utility of uterine artery Doppler velocimetry in prediction of preeclampsia in a low-risk population. Obstet Gynecol. 2012 Oct;120(4):815-22.</citation>
    <PMID>22996099</PMID>
  </reference>
  <reference>
    <citation>Weissgerber TL, Gandley RE, McGee PL, Spong CY, Myatt L, Leveno KJ, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Harper M, Tolosa JE, Saade G, Sorokin Y; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Haptoglobin phenotype, preeclampsia risk and the efficacy of vitamin C and E supplementation to prevent preeclampsia in a racially diverse population. PLoS One. 2013;8(4):e60479. doi: 10.1371/journal.pone.0060479. Epub 2013 Apr 3.</citation>
    <PMID>23573260</PMID>
  </reference>
  <reference>
    <citation>Johnson J, Clifton RG, Roberts JM, Myatt L, Hauth JC, Spong CY, Varner MW, Wapner RJ, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Samuels P, Sciscione A, Harper M, Tolosa JE, Saade G, Sorokin Y; Eunice Kennedy Shriver National Institute of Child Health; Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Pregnancy outcomes with weight gain above or below the 2009 Institute of Medicine guidelines. Obstet Gynecol. 2013 May;121(5):969-75. doi: 10.1097/AOG.0b013e31828aea03.</citation>
    <PMID>23635732</PMID>
  </reference>
  <reference>
    <citation>Myatt L, Clifton RG, Roberts JM, Spong CY, Wapner RJ, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Sciscione A, Tolosa JE, Saade G, Sorokin Y, Anderson GD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? BJOG. 2013 Sep;120(10):1183-91. doi: 10.1111/1471-0528.12128. Epub 2013 Jan 18.</citation>
    <PMID>23331974</PMID>
  </reference>
  <reference>
    <citation>Makhlouf MA, Clifton RG, Roberts JM, Myatt L, Hauth JC, Leveno KJ, Varner MW, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Iams JD, Sciscione A, Tolosa JE, Sorokin Y; Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network. Adverse pregnancy outcomes among women with prior spontaneous or induced abortions. Am J Perinatol. 2014 Oct;31(9):765-72. doi: 10.1055/s-0033-1358771. Epub 2013 Dec 17.</citation>
    <PMID>24347257</PMID>
  </reference>
  <reference>
    <citation>Cantu J, Clifton RG, Roberts JM, Leveno KJ, Myatt L, Reddy UM, Varner MW, Wapner RJ, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Samuels P, Sciscione A, Saade G, Sorokin Y; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Laboratory abnormalities in pregnancy-associated hypertension: frequency and association with pregnancy outcomes. Obstet Gynecol. 2014 Nov;124(5):933-40. doi: 10.1097/AOG.0000000000000509.</citation>
    <PMID>25437721</PMID>
  </reference>
  <reference>
    <citation>Weissgerber TL, McGee PL, Myatt L, Hauth JC, Varner MW, Wapner RJ, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Samuels P, Sciscione AC, Harper M, Saade G, Sorokin Y; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Haptoglobin phenotype and abnormal uterine artery Doppler in a racially diverse cohort. J Matern Fetal Neonatal Med. 2014 Nov;27(17):1728-33. doi: 10.3109/14767058.2013.876622. Epub 2014 Jan 13.</citation>
    <PMID>24345080</PMID>
  </reference>
  <reference>
    <citation>Abramovici A, Gandley RE, Clifton RG, Leveno KJ, Myatt L, Wapner RJ, Thorp JM Jr, Mercer BM, Peaceman AM, Samuels P, Sciscione A, Harper M, Saade G, Sorokin Y; Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network. Prenatal vitamin C and E supplementation in smokers is associated with reduced placental abruption and preterm birth: a secondary analysis. BJOG. 2015 Dec;122(13):1740-7. doi: 10.1111/1471-0528.13201. Epub 2014 Dec 17.</citation>
    <PMID>25516497</PMID>
  </reference>
  <reference>
    <citation>Basraon SK, Mele L, Myatt L, Roberts JM, Hauth JC, Leveno KJ, Varner MW, Wapner RJ, Thorp JM Jr, Peaceman AM, Ramin SM, Sciscione A, Tolosa JE, Sorokin Y; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. Relationship of Early Pregnancy Waist-to-Hip Ratio versus Body Mass Index with Gestational Diabetes Mellitus and Insulin Resistance. Am J Perinatol. 2016 Jan;33(1):114-21. doi: 10.1055/s-0035-1562928. Epub 2015 Sep 9.</citation>
    <PMID>26352680</PMID>
  </reference>
  <reference>
    <citation>McDonnold M, Mele LM, Myatt L, Hauth JC, Leveno KJ, Reddy UM, Mercer BM; Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units (MFMU) Network. Waist-to-Hip Ratio versus Body Mass Index as Predictor of Obesity-Related Pregnancy Outcomes. Am J Perinatol. 2016 May;33(6):618-24. doi: 10.1055/s-0035-1569986. Epub 2016 Jan 20.</citation>
    <PMID>26788786</PMID>
  </reference>
  <reference>
    <citation>Hughes BL, Clifton RG, Hauth JC, Leveno KJ, Myatt L, Reddy UM, Varner MW, Wapner RJ, Mercer BM, Peaceman AM, Ramin SM, Tolosa JE, Saade G, Sorokin Y; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Is Mid-trimester Insulin Resistance Predictive of Subsequent Puerperal Infection? A Secondary Analysis of Randomized Trial Data. Am J Perinatol. 2016 Aug;33(10):983-90. doi: 10.1055/s-0036-1583188. Epub 2016 Apr 27.</citation>
    <PMID>27120478</PMID>
  </reference>
  <reference>
    <citation>Silver RM, Myatt L, Hauth JC, Leveno KJ, Peaceman AM, Ramin SM, Samuels P, Saade G, Sorokin Y, Clifton RG, Reddy UM. Cell-Free Total and Fetal DNA in First Trimester Maternal Serum and Subsequent Development of Preeclampsia. Am J Perinatol. 2017 Jan;34(2):191-198. doi: 10.1055/s-0035-1570383. Epub 2016 Jul 11.</citation>
    <PMID>27398706</PMID>
  </reference>
  <reference>
    <citation>Tita AT, Doherty L, Roberts JM, Myatt L, Leveno KJ, Varner MW, Wapner RJ, Thorp JM Jr, Mercer BM, Peaceman A, Ramin SM, Carpenter MW, Iams J, Sciscione A, Harper M, Tolosa JE, Saade GR, Sorokin Y; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Adverse Maternal and Neonatal Outcomes in Indicated Compared with Spontaneous Preterm Birth in Healthy Nulliparas: A Secondary Analysis of a Randomized Trial. Am J Perinatol. 2018 Jun;35(7):624-631. doi: 10.1055/s-0037-1608787. Epub 2017 Nov 30.</citation>
    <PMID>29190847</PMID>
  </reference>
  <results_reference>
    <citation>Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ, Pearson GD, Wapner RJ, Varner MW, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Harper M, Smith WJ, Saade G, Sorokin Y, Anderson GB; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med. 2010 Apr 8;362(14):1282-91. doi: 10.1056/NEJMoa0908056.</citation>
    <PMID>20375405</PMID>
  </results_reference>
  <results_reference>
    <citation>Hauth JC, Clifton RG, Roberts JM, Spong CY, Myatt L, Leveno KJ, Pearson GD, Varner MW, Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Sciscione A, Harper M, Tolosa JE, Saade G, Sorokin Y, Anderson GB; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units Network (MFMU). Vitamin C and E supplementation to prevent spontaneous preterm birth: a randomized controlled trial. Obstet Gynecol. 2010 Sep;116(3):653-8. doi: 10.1097/AOG.0b013e3181ed721d.</citation>
    <PMID>20733448</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 24, 2005</study_first_submitted>
  <study_first_submitted_qc>August 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2005</study_first_posted>
  <results_first_submitted>November 1, 2012</results_first_submitted>
  <results_first_submitted_qc>October 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2018</results_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antioxidants</keyword>
  <keyword>Preeclampsia</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be shared after completion of the trial an publication of the main analyses per NIH Policy. Requests should be emailed to mfmudatasets@bsc.gwu.edu.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted from July 2003 through February 2008 at the 16 clinical centers and the independent data coordinating center of the MFMU Network. Gestational age at randomization was between 9 weeks 0 days and 16 weeks 6 days. Women were eligible for inclusion if they had not had a previous pregnancy that lasted beyond 19 weeks 6 days.</recruitment_details>
      <pre_assignment_details>Women who were no more than 15 weeks pregnant and who consented to participate in the study were given a supply of placebo and asked to return within 2 weeks. Those who returned, who had taken at least 50% of the placebo they were supposed to have taken, and who still met the eligibility criteria were randomly assigned to receive study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamins</title>
          <description>Vitamins C &amp; E</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5088"/>
                <participants group_id="P2" count="5066"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4993"/>
                <participants group_id="P2" count="4976"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Institutional review board request</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Daily Vitamin Supplements</title>
          <description>1000mg of Vitamin C and 400IU of Vitamin E per capsule, twice daily between randomization (at 9 to 16 weeks) up to delivery.</description>
        </group>
        <group group_id="B2">
          <title>Placebo for Vitamins C and E</title>
          <description>Placebo capsules consisting of Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell, twice daily between randomization (at 9 to 16 weks) up to delivery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5087"/>
            <count group_id="B2" value="5065"/>
            <count group_id="B3" value="10152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.5" spread="5.2"/>
                    <measurement group_id="B2" value="23.5" spread="5.2"/>
                    <measurement group_id="B3" value="23.5" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5087"/>
                    <measurement group_id="B2" value="5065"/>
                    <measurement group_id="B3" value="10152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race or ethnic group was self-reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1268"/>
                    <measurement group_id="B2" value="1295"/>
                    <measurement group_id="B3" value="2563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1602"/>
                    <measurement group_id="B2" value="1566"/>
                    <measurement group_id="B3" value="3168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2217"/>
                    <measurement group_id="B2" value="2204"/>
                    <measurement group_id="B3" value="4421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Week of pregnancy at randomization</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.4" spread="2.1"/>
                    <measurement group_id="B2" value="13.4" spread="2.1"/>
                    <measurement group_id="B3" value="13.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>&lt;13th week of pregnancy at randomization</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2227"/>
                    <measurement group_id="B2" value="2203"/>
                    <measurement group_id="B3" value="4430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prepregnancy body-mass index</title>
          <description>The body-mass index is the weight in kilograms divided by the square of the height in meters. Prepregnancy weight used to calculate body-mass index was self-reported. Values were unavailable for 99 women in the vitamin group and 111 in the placebo group.</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.4" spread="6.0"/>
                    <measurement group_id="B2" value="25.4" spread="5.9"/>
                    <measurement group_id="B3" value="25.4" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="812"/>
                    <measurement group_id="B2" value="781"/>
                    <measurement group_id="B3" value="1593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Educational level</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.8" spread="2.7"/>
                    <measurement group_id="B2" value="12.8" spread="2.7"/>
                    <measurement group_id="B3" value="12.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of prenatal vitamins or multivitamins</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3903"/>
                    <measurement group_id="B2" value="3889"/>
                    <measurement group_id="B3" value="7792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily dose of vitamin C</title>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120" lower_limit="50" upper_limit="120"/>
                    <measurement group_id="B2" value="100" lower_limit="50" upper_limit="120"/>
                    <measurement group_id="B3" value="100" lower_limit="50" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily dose of vitamin E</title>
          <units>IU</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" lower_limit="3" upper_limit="30"/>
                    <measurement group_id="B2" value="22" lower_limit="0" upper_limit="30"/>
                    <measurement group_id="B3" value="22" lower_limit="2" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous pregnancy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1161"/>
                    <measurement group_id="B2" value="1170"/>
                    <measurement group_id="B3" value="2331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family history of preeclampsia</title>
          <description>Family history is based on self-reported preeclampsia in a first-degree relative (mother, sister, or grandmother).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="650"/>
                    <measurement group_id="B2" value="674"/>
                    <measurement group_id="B3" value="1324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109" spread="10"/>
                    <measurement group_id="B2" value="109" spread="10"/>
                    <measurement group_id="B3" value="109" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="8"/>
                    <measurement group_id="B2" value="65" spread="8"/>
                    <measurement group_id="B3" value="65" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate</title>
        <description>Severe hypertension (blood pressure [BP]&gt;= 160/110) or mild hypertension (BP&gt;= 140/90) &gt;= 20 weeks gestation in conjunction with one of the following: elevated liver enzymes, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, an indicated preterm birth before 32 weeks of gestation owing to hypertension-related disorders, a fetus that was small for gestational age (below 3rd percentile) adjusted for sex and race or ethnic group, fetal death after 20 weeks of gestation, or neonatal death</description>
        <time_frame>20 weeks through discharge following delivery</time_frame>
        <population>The analysis was intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate</title>
          <description>Severe hypertension (blood pressure [BP]&gt;= 160/110) or mild hypertension (BP&gt;= 140/90) &gt;= 20 weeks gestation in conjunction with one of the following: elevated liver enzymes, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, an indicated preterm birth before 32 weeks of gestation owing to hypertension-related disorders, a fetus that was small for gestational age (below 3rd percentile) adjusted for sex and race or ethnic group, fetal death after 20 weeks of gestation, or neonatal death</description>
          <population>The analysis was intent to treat.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305"/>
                    <measurement group_id="O2" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary hypothesis states that antioxidant therapy initiated prior to 16 weeks gestation in women will reduce the frequency of serious maternal and infant complications associated with pregnancy related hypertension. We estimated that with a sample size of 10,000 women, the study would have 90% power to show a 30% reduction in the rate of the primary outcome, from 4% in the placebo to 2.8% in the vitamin group, with a two-sided type I error rate of 5%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severe Hypertension</title>
        <description>Included here are women who had severe hypertension only and those who had severe hypertension with elevated liver enzyme levels, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, medically indicated preterm birth, fetal-growth restriction, or fetal death after 20 weeks of gestation, or neonatal death.</description>
        <time_frame>20 weeks through discharge following delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Hypertension</title>
          <description>Included here are women who had severe hypertension only and those who had severe hypertension with elevated liver enzyme levels, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, medically indicated preterm birth, fetal-growth restriction, or fetal death after 20 weeks of gestation, or neonatal death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severe or Mild Pregnancy-associated Hypertension With Elevated Liver Enzyme Levels</title>
        <description>Elevated liver enzyme levels are specified as an aspartate aminotransferase level of &gt;= 100 U per liter. Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
        <time_frame>20 weeks through discharge following delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Severe or Mild Pregnancy-associated Hypertension With Elevated Liver Enzyme Levels</title>
          <description>Elevated liver enzyme levels are specified as an aspartate aminotransferase level of &gt;= 100 U per liter. Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severe or Mild Pregnancy-associated Hypertension With Thrombocytopenia</title>
        <description>Thrombocytopenia defined as a platelet count of &lt;100,000 per cubic millimeter. Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
        <time_frame>20 weeks through discharge following delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Severe or Mild Pregnancy-associated Hypertension With Thrombocytopenia</title>
          <description>Thrombocytopenia defined as a platelet count of &lt;100,000 per cubic millimeter. Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severe or Mild Pregnancy-associated Hypertension With an Elevated Serum Creatinine Level</title>
        <description>Elevated serum creatinine defined as ≥1.5 mg per deciliter or 132.6 μmol per liter. Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
        <time_frame>20 weeks through discharge following delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Severe or Mild Pregnancy-associated Hypertension With an Elevated Serum Creatinine Level</title>
          <description>Elevated serum creatinine defined as ≥1.5 mg per deciliter or 132.6 μmol per liter. Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severe or Mild Pregnancy-associated Hypertension With an Eclamptic Seizure</title>
        <description>Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
        <time_frame>20 weeks through discharge following delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Severe or Mild Pregnancy-associated Hypertension With an Eclamptic Seizure</title>
          <description>Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>7.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severe or Mild Pregnancy-associated Hypertension With an Indicated Preterm Birth Before 32 Weeks of Gestation Owing to Hypertension-related Disorders</title>
        <description>Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
        <time_frame>20 weeks through discharge following delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Severe or Mild Pregnancy-associated Hypertension With an Indicated Preterm Birth Before 32 Weeks of Gestation Owing to Hypertension-related Disorders</title>
          <description>Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severe or Mild Pregnancy-associated Hypertension With a Fetus That Was Small for Gestational Age (Below the 3rd Percentile) Adjusted for Sex and Race or Ethnic Group</title>
        <description>Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
        <time_frame>20 weeks through discharge following delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Severe or Mild Pregnancy-associated Hypertension With a Fetus That Was Small for Gestational Age (Below the 3rd Percentile) Adjusted for Sex and Race or Ethnic Group</title>
          <description>Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severe or Mild Pregnancy-associated Hypertension With a Fetal Death After 20 Weeks of Gestation or Neonatal Death</title>
        <description>Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
        <time_frame>20 weeks through discharge or prior to discharge following delivery admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Severe or Mild Pregnancy-associated Hypertension With a Fetal Death After 20 Weeks of Gestation or Neonatal Death</title>
          <description>Women who met more than one component of the primary outcome were counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>2.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preeclampsia (Mild, Severe, HELLP Syndrome, Eclampsia)</title>
        <description>HELLP denotes hemolytic anemia, elevated liver enzymes, and low platelet count.</description>
        <time_frame>20 weeks through discharge following delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Preeclampsia (Mild, Severe, HELLP Syndrome, Eclampsia)</title>
          <description>HELLP denotes hemolytic anemia, elevated liver enzymes, and low platelet count.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Preeclampsia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358"/>
                    <measurement group_id="O2" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild Preeclampsia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Preeclampsia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HELLP Syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eclampsia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pregnancy Associated Hypertension</title>
        <time_frame>20 weeks through discharge following delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnancy Associated Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1457"/>
                    <measurement group_id="O2" value="1322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medically Indicated Delivery Because of Hypertension</title>
        <time_frame>20 weeks through discharge following delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Medically Indicated Delivery Because of Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4952"/>
                <count group_id="O2" value="4934"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509"/>
                    <measurement group_id="O2" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase ≥100 U/Liter</title>
        <time_frame>20 weeks through discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase ≥100 U/Liter</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine ≥1.5 mg/dl (133 μmol/Liter)</title>
        <time_frame>20 weeks through discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine ≥1.5 mg/dl (133 μmol/Liter)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antepartum Bleeding</title>
        <time_frame>During pregnancy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Antepartum Bleeding</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4956"/>
                <count group_id="O2" value="4937"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Premature Rupture of Membranes</title>
        <time_frame>During pregnancy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Premature Rupture of Membranes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4934"/>
                <count group_id="O2" value="4923"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Placental Abruption</title>
        <time_frame>During pregnancy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Placental Abruption</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4957"/>
                <count group_id="O2" value="4938"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cesarean Delivery</title>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Cesarean Delivery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4958"/>
                <count group_id="O2" value="4940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1269"/>
                    <measurement group_id="O2" value="1224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Death</title>
        <time_frame>Delivery through hospital discharge</time_frame>
        <population>One maternal death in each group due to peripartum cardiomyopathy.</population>
        <group_list>
          <group group_id="O1">
            <title>Dietary Supplement/Vitamins</title>
            <description>1000mg of Vitamin C and 400IU of Vitamin E per capsule, twice daily between randomization (at 9 to 16 weeks) up to delivery.
Dietary Supplement/Vitamins: Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Vitamin C and Vitamin E</title>
            <description>Placebo capsules consisting of Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell, twice daily between randomization (at 9 to 16 weks) up to delivery.
Placebo for Vitamin C and Vitamin E: Placebo two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Death</title>
          <population>One maternal death in each group due to peripartum cardiomyopathy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postpartum Pulmonary Edema</title>
        <time_frame>After delivery through discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Postpartum Pulmonary Edema</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4951"/>
                <count group_id="O2" value="4926"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematocrit ≤24% With Transfusion</title>
        <time_frame>Delivery admission to discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Hematocrit ≤24% With Transfusion</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4954"/>
                <count group_id="O2" value="4927"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Hospital Stay</title>
        <time_frame>Delivery through discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Hospital Stay</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4952"/>
                <count group_id="O2" value="4935"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="2.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="2.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Age at Delivery</title>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Age at Delivery</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" spread="3.5"/>
                    <measurement group_id="O2" value="38.8" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preterm Birth</title>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Preterm Birth</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;37 weeks' gestation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="513"/>
                    <measurement group_id="O2" value="526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;32 weeks' gestation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>&lt;37 weeks' gestation</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>&lt;32 weeks' gestation</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fetal or Neonatal Death</title>
        <time_frame>During pregnancy or thorugh discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal or Neonatal Death</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4993"/>
                <count group_id="O2" value="4976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Fetal or Neonatal Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fetal loss at &lt; 20 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fetal death at ≥20 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neonatal death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Birth Weight</title>
        <time_frame>At birth</time_frame>
        <population>Liveborn infants</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Birth Weight</title>
          <population>Liveborn infants</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4900"/>
                <count group_id="O2" value="4881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3247" spread="575"/>
                    <measurement group_id="O2" value="3244" spread="581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Small for Gestational Age</title>
        <description>A baby whose birth weight is less than the 3rd percentile is considered to be small for gestational age (adjusted for sex and race or ethnic group)</description>
        <time_frame>At birth</time_frame>
        <population>Live born infants</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Small for Gestational Age</title>
          <description>A baby whose birth weight is less than the 3rd percentile is considered to be small for gestational age (adjusted for sex and race or ethnic group)</description>
          <population>Live born infants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4900"/>
                <count group_id="O2" value="4881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Birth Weight &lt;2500 Grams</title>
        <time_frame>At birth</time_frame>
        <population>Live born infants</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Birth Weight &lt;2500 Grams</title>
          <population>Live born infants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4900"/>
                <count group_id="O2" value="4881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345"/>
                    <measurement group_id="O2" value="369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Admission to NICU</title>
        <description>NICU denotes neonatal intensive care unit.</description>
        <time_frame>Delivery through discharge</time_frame>
        <population>Live born infants</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Admission to NICU</title>
          <description>NICU denotes neonatal intensive care unit.</description>
          <population>Live born infants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4900"/>
                <count group_id="O2" value="4881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="577"/>
                    <measurement group_id="O2" value="557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Distress Syndrome</title>
        <time_frame>Delivery through discharge</time_frame>
        <population>Live born infants</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Distress Syndrome</title>
          <population>Live born infants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4900"/>
                <count group_id="O2" value="4881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraventricular Hemorrhage, Grade III or IV</title>
        <time_frame>Delivery through discharge</time_frame>
        <population>Live born infants</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Intraventricular Hemorrhage, Grade III or IV</title>
          <population>Live born infants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4900"/>
                <count group_id="O2" value="4881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>2.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sepsis</title>
        <time_frame>Delivery through discharge</time_frame>
        <population>Live born infants</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Sepsis</title>
          <population>Live born infants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4900"/>
                <count group_id="O2" value="4881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Necrotizing Enterocolitis</title>
        <time_frame>Delivery through discharge</time_frame>
        <population>Live born infants</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Necrotizing Enterocolitis</title>
          <population>Live born infants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4900"/>
                <count group_id="O2" value="4881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retinopathy of Prematurity</title>
        <time_frame>Within 1 month of birth</time_frame>
        <population>Live born infants</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Retinopathy of Prematurity</title>
          <population>Live born infants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4900"/>
                <count group_id="O2" value="4881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>2.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apgar Score &lt;=3 at 5 Minutes</title>
        <time_frame>At birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Apgar Score &lt;=3 at 5 Minutes</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4900"/>
                <count group_id="O2" value="4881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Hospital Stay</title>
        <time_frame>Birth through discharge from hospital</time_frame>
        <population>Live born infants</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Hospital Stay</title>
          <population>Live born infants</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4900"/>
                <count group_id="O2" value="4881"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="2.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="2.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Analysis of Primary Composite Outcome in Participants Randomized on or After the 13th Week of Pregnancy</title>
        <description>Subgroup analysis of the primary composite outcome (severe pregnancy associated hypertension or severe or mild hypertension with elevated liver-enzyme levels, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, indicated preterm birth, fetal-growth restriction or prenatal death) in participants who were randomized on or after the 13th week of pregnancy.</description>
        <time_frame>During pregnancy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>1000mg of Vitamin C and 400IU of Vitamin E per capsule, twice daily between randomization (at 9 to 16 weeks) up to delivery.
Dietary Supplement/Vitamins: Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules consisting of Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell, twice daily between randomization (at 9 to 16 weks) up to delivery.
Placebo for Vitamin C and Vitamin E: Placebo two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Primary Composite Outcome in Participants Randomized on or After the 13th Week of Pregnancy</title>
          <description>Subgroup analysis of the primary composite outcome (severe pregnancy associated hypertension or severe or mild hypertension with elevated liver-enzyme levels, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, indicated preterm birth, fetal-growth restriction or prenatal death) in participants who were randomized on or after the 13th week of pregnancy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2812"/>
                <count group_id="O2" value="2814"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Analysis of Primary Composite Outcome in Participants Randomized Before the 13th Week of Pregnancy</title>
        <description>Subgroup analysis of the primary composite outcome (severe pregnancy associated hypertension or severe or mild hypertension with elevated liver-enzyme levels, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, indicated preterm birth, fetal-growth restriction or prenatal death) in participants who were randomized before the 13th week of pregnancy.</description>
        <time_frame>During pregnancy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamins</title>
            <description>Vitamins C &amp; E</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Primary Composite Outcome in Participants Randomized Before the 13th Week of Pregnancy</title>
          <description>Subgroup analysis of the primary composite outcome (severe pregnancy associated hypertension or severe or mild hypertension with elevated liver-enzyme levels, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, indicated preterm birth, fetal-growth restriction or prenatal death) in participants who were randomized before the 13th week of pregnancy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2181"/>
                <count group_id="O2" value="2162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected beginning with enrollment (between 9 weeks 0 days gestation and 16 weeks 6 days gestation) through the duration of the pregnancy, delivery, and hospital discharge for the mother and baby. This time period varies by participant and may cover anywhere from 9 weeks gestation to 42 weeks gestation.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vitamins</title>
          <description>Vitamins C &amp; E</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5065"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="173" subjects_at_risk="5065"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5065"/>
              </event>
              <event>
                <sub_title>Infant low platelet count</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5065"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Peripartum Cardiomyopathy</sub_title>
                <description>Peripartum Cardiomyopathy resulting in death.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5065"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5065"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Fetal birth defects</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="5065"/>
              </event>
              <event>
                <sub_title>Fetal atrial flutter/arrythmia/bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5065"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal death</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="5065"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Group A strep sepsis, bacterial/ viral meningitis, cellulitis, sepsis, bacterial infection</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5065"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Birth injury</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5065"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5065"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Infant - Soft Tissue Mass</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5065"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Infant Seizures</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5065"/>
              </event>
              <event>
                <sub_title>Hypoxic Events</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Hypoxic birth injury, hypoxic ischemic encephalopathy, ischemic stroke</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5065"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Fetal Death</sub_title>
                <description>Miscarriage, stillbirth, abortion</description>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="5065"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Placental abruption, vaginal bleeding</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="5065"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <description>Postpartum hemorrhage, blood transfusion, hysterectomy</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5065"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and Urinary disorders</sub_title>
                <description>Pyelonephritis and Urinary Tract Infection</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="5065"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory distress/pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5065"/>
              </event>
              <event>
                <sub_title>DVT/PE</sub_title>
                <description>Deep vein thrombosis, pulmonary embolism</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5065"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Colon resection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5065"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5087"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5065"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. James Roberts</name_or_title>
      <organization>Dept of Obstetrics and Gynecology, University of Pittsburgh</organization>
      <phone>412-641-1427</phone>
      <email>RSIJMR@mwri.magee.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

